These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22644706)

  • 1. Investigation of formulation variables and excipient interaction on the production of niosomes.
    Sezgin-Bayindir Z; Yuksel N
    AAPS PharmSciTech; 2012 Sep; 13(3):826-35. PubMed ID: 22644706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery.
    Bayindir ZS; Yuksel N
    J Pharm Sci; 2010 Apr; 99(4):2049-60. PubMed ID: 19780133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preformulation characterization and identification of excipients for nevirapine loaded niosomes.
    Witika BA; Walker RB
    Pharmazie; 2021 Feb; 76(2):77-83. PubMed ID: 33714283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of formulation compositions on niosomal preparations.
    Chaw CS; Kim KY
    Pharm Dev Technol; 2013; 18(3):667-72. PubMed ID: 22468904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of green formulation technique and efficacy estimation on cell line studies for dual anticancer drug therapy with niosomes.
    Khan DH; Bashir S; Correia A; Khan MI; Figueiredo P; Santos HA; Peltonen L
    Int J Pharm; 2019 Dec; 572():118764. PubMed ID: 31628977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorbitane Monostearate and Cholesterol based Niosomes for Oral Delivery of Telmisartan.
    Ahad A; Raish M; Al-Jenoobi FI; Al-Mohizea AM
    Curr Drug Deliv; 2018 Feb; 15(2):260-266. PubMed ID: 28521674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α-Tocopherol-loaded niosome prepared by heating method and its release behavior.
    Basiri L; Rajabzadeh G; Bostan A
    Food Chem; 2017 Apr; 221():620-628. PubMed ID: 27979250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes.
    Mokhtar M; Sammour OA; Hammad MA; Megrab NA
    Int J Pharm; 2008 Sep; 361(1-2):104-11. PubMed ID: 18577437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and in vitro characterization of small unilamellar niosomes as ophthalmic carrier of dorzolamide hydrochloride.
    Hasan AA
    Pharm Dev Technol; 2014 Sep; 19(6):748-54. PubMed ID: 23964893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and development of cefdinir niosomes for oral delivery.
    Bansal S; Aggarwal G; Chandel P; Harikumar SL
    J Pharm Bioallied Sci; 2013 Oct; 5(4):318-25. PubMed ID: 24302841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation and investigation of pilocarpine hydrochloride niosomal gels for the treatment of glaucoma: intraocular pressure measurement in white albino rabbits.
    Jain N; Verma A; Jain N
    Drug Deliv; 2020 Dec; 27(1):888-899. PubMed ID: 32551978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery.
    Balakrishnan P; Shanmugam S; Lee WS; Lee WM; Kim JO; Oh DH; Kim DD; Kim JS; Yoo BK; Choi HG; Woo JS; Yong CS
    Int J Pharm; 2009 Jul; 377(1-2):1-8. PubMed ID: 19394413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of montelukast sodium loaded niosomal carriers by film hydration technique.
    Kumar S; Awasthi R
    Antiinflamm Antiallergy Agents Med Chem; 2015; 14(1):63-78. PubMed ID: 25910042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol entrapped niosomes as yoghurt additive.
    Pando D; Beltrán M; Gerone I; Matos M; Pazos C
    Food Chem; 2015 Mar; 170():281-7. PubMed ID: 25306346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation, Characterization and
    Patel P; Barot T; Kulkarni P
    Curr Drug Deliv; 2020; 17(3):257-268. PubMed ID: 32056523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Surfactant Type, Cholesterol Content and Various Downsizing Methods on the Particle Size of Niosomes.
    Nowroozi F; Almasi A; Javidi J; Haeri A; Dadashzadeh S
    Iran J Pharm Res; 2018; 17(Suppl2):1-11. PubMed ID: 31011337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of charged and non-ionic membrane additives on physicochemical properties and stability of niosomes.
    Junyaprasert VB; Teeranachaideekul V; Supaperm T
    AAPS PharmSciTech; 2008; 9(3):851-9. PubMed ID: 18636334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating the role of cholesterol in the formation of non-ionic surfactant based bilayer vesicles: thermal analysis and molecular dynamics.
    Wilkhu JS; Ouyang D; Kirchmeier MJ; Anderson DE; Perrie Y
    Int J Pharm; 2014 Jan; 461(1-2):331-41. PubMed ID: 24333900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro characterisation of Span 65 niosomal formulations containing proteins.
    Haj-Ahmad RR; Elkordy AA; Chaw CS
    Curr Drug Deliv; 2015; 12(5):628-39. PubMed ID: 25963305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and characterization of 5-fluorouracil pH-sensitive niosome and its tumor-targeted evaluation: in vitro and in vivo.
    Wang M; Yuan Y; Gao Y; Ma HM; Xu HT; Zhang XN; Pan WS
    Drug Dev Ind Pharm; 2012 Sep; 38(9):1134-41. PubMed ID: 22182601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.